Effectiveness of prednisolone in treatment of multiple myeloma

Phase 2

Recruiting

• Conditions: multiple myeloma.; Multiple myeloma

• Registration Number: IRCT2017032633143N1
• Lead Sponsor: Personal

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Newly diagnosed patients with multiple myeloma who have over 18 years of age and are willing to participate in this study.
Exclusion criteria: HIV-positive patients, patients with a history of malignant, uncontrolled diabetes, neuropathy grade 2 diabetes, significant liver and kidney and heart failure are excluded.

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Effectiveness. Timepoint: After 4 courses of treatment. Method of measurement: Check list and interviews.;Side effects. Timepoint: After 4 courses of treatment. Method of measurement: Check list and interviews.

Secondary Outcome Measures

Name	Time	Method
Plt changes. Timepoint: After 4 courses of treatment. Method of measurement: check list and interviews.;Neuropathy. Timepoint: After 4 courses of treatment. Method of measurement: check list and interviews.;The cost of treatment. Timepoint: After 4 courses of treatment. Method of measurement: check list and interviews.;WBC changes. Timepoint: After 4 courses of treatment. Method of measurement: check list and interviews.;The number of pack cell. Timepoint: After 4 courses of treatment. Method of measurement: check list and interviews.;Quality of Life. Timepoint: After 4 courses of treatment. Method of measurement: check list and interviews.